SecurityETTX / Entasis Therapeutics Holdings Inc.
President and CEOPerros Manoussos
Institutional Owners0

Institutional Stock Ownership and Shareholders

Entasis Therapeutics Holdings Inc. (NASDAQ:ETTX) has 0 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). Largest shareholders include .
Entasis Therapeutics Holdings Inc. (NASDAQ:ETTX) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds more than 5% of the company and intends to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%. Green rows indicate new positions. Red rows indicate closed positions. Click the link icon to see the full transaction history.

Important Note!
Note: We do not currently have a CUSIP on file for this security. That means we are unable to search institutional fund filings (13F's) for this company, which means there may be institutional holders that we are unaware of. If you know the CUSIP or would like us to research and update this security, please let us know by leaving a message in the Welcome Group.
File DateFormInvestor Opt Prev
Shares
Current
Shares
Change
(Percent)
Prev Value
($1000)
Current Value
($1000)
Change
(Percent)

Related News Stories

IPO News This Week: 6 Firms to Test the Market

2018-09-30 247wallst
Last week’s initial public offering (IPO) action saw 12 companies launch successful offerings that raised $1.2 billion in new capital. A total of six IPOs are scheduled to launch in the coming week seeking a total of $658 million in new capital. (0-1)

U.S. IPO Weekly Recap: 12 IPOs Wrap Up Active Third Quarter As SurveyMonkey Pops 34%

2018-09-29 seekingalpha
The third quarter finished with 12 IPOs raising $1.2 billion, tied for the most active week of the year. Returns varied, but the group averaged a gain of just 1.0%. (0-1)

On the Heels of bluebird bio Collaboration, Gritstone Secures $100 Million in IPO

2018-09-28 biospace
Emeryville, Calif.-based Gritstone Oncology hits the ground running today on the Nasdaq Exchange after raising $100 million in an initial public offering. (0-2)